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Abstract
Aim: MRP2 is an intestinal ABC transporter that prevents the absorption of dietary 
xenobiotics. The aims of this work were: i) to evaluate whether a short-term regulation of 
intestinal MRP2 barrier function takes place in vivo after luminal incorporation of nutrients 
and ii) to explore the underlying mechanism.
Methods: MRP2 activity and localization were assessed in an in vivo rat model with 
preserved irrigation and innervation. Nutrients were administered into distal jejunum. 
After 30-min treatments, MRP2 activity was assessed in proximal jejunum by quantifying 
the transport of the model substrate 2,4-dinitrophenyl-S-glutathione. MRP2 localization 
was determined by quantitative confocal microscopy. Participation of extracellular 
mediators was evaluated using selective inhibitors and by immunoneutralization. 
Intracellular pathways were explored in differentiated Caco-2 cells.
Results: Oleic acid, administered intraluminally at dietary levels, acutely stimulated MRP2 
insertion into brush border membrane. This was associated with increased efflux activity 
and, consequently, enhanced barrier function. Immunoneutralization of the gut hormone 
glucagon-like peptide-2 (GLP-2) prevented oleic acid effect on MRP2, demonstrating the 
participation of this trophic factor as a main mediator. Further experiments using selective 
inhibitors demonstrated that extracellular adenosine synthesis and its subsequent binding 
to enterocytic A2B adenosine receptor (A2BAR) take place downstream GLP-2. Finally, 
studies in intestinal Caco-2 cells revealed the participation of A2BAR/cAMP/PKA 
intracellular pathway, ultimately leading to increased MRP2 localization in apical 
domains.
Conclusion: These findings reveal an on-demand, acute regulation of MRP2-associated 
barrier function, constituting a novel physiological mechanism of protection against the 
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1. Introduction
The small intestine constitutes a biochemical barrier between external and internal 
environments which depends on the proper localization and activity of ATP-binding 
cassette (ABC) transporters. ABC efflux pumps, particularly localized to the brush border 
membrane (BBM) of the enterocyte, are responsible for actively extruding xenobiotics 
back to the intestinal lumen. Among these transporters, the multidrug resistance-
associated protein 2 (MRP2; also known as ABCC2) has a wide substrate specificity, 
limiting the absorption of numerous prescription drugs and food contaminants.1,2 
Intestinal MRP2 expression and localization were first described two decades ago. 
Enterocytes from the tip of the villus exhibited the maximal MRP2 expression with a 
decreasing pattern towards the cells from the crypt. A gradient along the intestinal tract 
was also found, with the highest MRP2 content in proximal jejunum decreasing towards 
the ileum.3,4 Although these studies have been performed in rats, a similar distribution 
was subsequently demonstrated in humans.5,6 MRP2 relevance as a key component of 
the intestinal barrier was demonstrated using TR- rats, in which this transporter is 
hereditarily defective. As result of oral bioavailability studies, TR- rats showed increased 
absorption, plasma concentration and tissue accumulation of the dietary carcinogen 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) when compared to normal Wistar 
rats.7
Glucagon-like peptide-2 (GLP-2) is a 33 amino acid peptide produced by enteroendocrine 
L cells from distal jejunum, ileum and colon epithelia. Its vast repertoire of actions at the 
intestinal level includes both long-term and short-term effects focused on improving 
intestinal functions such as digestion and absorption. Among long-term effects are the 
increase in proliferation and the decrease in apoptosis of epithelial cells, eventually 
leading to intestinal hypertrophy and hyperplasia.8-10 Among short-term effects, the most 
remarkable is the increase in intestinal blood flow after meals, also known as 
postprandial hyperemia.11,12 GLP-2 exerts these biological functions by binding to GLP-
2R, a G protein-coupled receptor expressed in enteric neurons, subepithelial 
myofibroblasts and enteroendocrine cells of the intestine.13 Interestingly, the presence of 
GLP-2R was ruled out both in epithelial crypt cells and in differentiated enterocytes, i.e. 
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level are exerted indirectly, through paracrine mediators produced by GLP-2R-expressing 
cells. While the polypeptide insulin-like growth factor-1 (IGF-1) was responsible for GLP-2 
intestinotrophic actions,14,15 the mediators behind GLP-2 acute effects are less known. 
However, indirect evidence suggests that enteric neurons and extracellularly generated 
adenosine could play a role in this regard.16,17
The main stimulus for GLP-2 release under physiological conditions is the presence of 
nutrients in the digestive tract. After food intake there is a biphasic increase in circulating 
levels of GLP-2. The first peak occurs within the first 15-30 min, when nutrients reach the 
duodenum. It is triggered by an indirect mechanism involving endocrine factors and the 
vagus nerve, ultimately resulting in muscarinic receptor-dependent L cell activation.18 The 
second peak occurs approximately 60-90 min after intake and involves direct luminal 
stimulation of L cells by nutrients. Interestingly, this second peak of GLP-2 secretion 
depends on the specific composition of the diet, with lipids and carbohydrates being more 
potent stimulators than proteins.19,20
Our group provided the first experimental evidence supporting the regulatory role of GLP-
2 on MRP2 function through transcriptional mechanisms.21 Additionally, subcutaneous 
administration of GLP-2 produced a significant increase in cAMP levels evaluated in rat 
enterocytes after 2 h of treatment. Moreover, a selective adenylate cyclase inhibitor 
prevented such increase, demonstrating activation of this enzymatic effector.21
Recently, we have reported that intestinal MRP2 localization may be subjected to a 
dynamic equilibrium between BBM and intracellular domains, thus allowing for rapid 
regulation of MRP2 function.22 This acute and bidirectional translocation was 
demonstrated for both rat and human orthologues using dibutyryl cAMP and estradiol-
17β-D-glucuronide. Particularly, we described the ability of cAMP to stimulate the 
insertion of MRP2 into the BBM. This effect was mediated by PKA and associated with 
increased secretory activity of the model substrate 2,4-dinitrophenyl-S-glutathione (DNP-
SG). In spite of all this evidence, it is unknown whether intestinal MRP2 acute regulation 
takes place in vivo as part of a physiological process.
The three main experimental findings described above can be summarized and 
sequentially linked as follows: (i) after intake of certain nutrients (such as oleic acid or 
glucose) GLP-2 is released from L cells;23 (ii) GLP-2 triggers an increase in cAMP levels 
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MRP2 into BBM with consequent impact on MRP2 transport activity.22 This sequence of 
events, although possible, needs experimental demonstration and constitutes our current 
working hypothesis. We here developed an appropriate in vivo model and demonstrated 
the occurrence of such events under physiological conditions. Moreover, we identified 
participation of additional and relevant extracellular mediators. These findings reveal a 
novel on-demand regulation of MRP2-associated barrier function, constituting an 
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2. Results
2.1. In vivo studies: Effect of nutrients on MRP2 activity and localization and 
elucidation of the extracellular mechanism involved.
2.1.1. The in vivo model provides a useful tool to detect rapid changes in MRP2 
activity.
First, we established whether the proinsertor agent dbcAMP acutely increases MRP2 
transport activity in our in vivo model when administered intravenously. As shown in 
Figure 1a, dbcAMP (20 µmol/kg b.w., 20 min) produced a significant increase (+213 % 
versus control) in DNP-SG efflux, demonstrating that this model allows for detection of 
rapid changes in MRP2 activity, at least in response to a systemic treatment.
2.1.2. Oleic acid acutely increases MRP2 activity.
We next evaluated the acute effect of GLP-2 releasing agents on MRP2 activity. Figure 
1b shows that, among the agents evaluated, only oleic acid and glucose were able to 
significantly modulate DNP-SG efflux in the proximal jejunum, suggesting a nutrient-
specific effect. Specifically, oleic acid, administered as an emulsion at a concentration of 
physiological relevance,24 increased MRP2 activity in comparison with its respective 
control group (+231 %). Intraluminal administration of saline + Tween 20 produced no 
effect on MRP2 activity when compared with saline alone (data not shown), ruling out any 
effect of the surfactant itself. In the case of glucose, an increase was observed at the 100 
mM (+186 %) but not at the 10 mM concentration, suggesting a dose-dependent effect. 
The effect of glutamine did not differ from that of the vehicle administered to control rats. 
Considering that intraluminal glucose concentrations of 100 mM are unlikely reached 
after a regular meal,25 we chose oleic acid as a prototype MRP2 modulating agent for the 
following studies aimed at elucidating the mechanism involved.
2.1.3. GLP-2 mediates oleic acid effect on MRP2 activity
The next step in testing our hypothesis was to evaluate the ability of GLP-2 to acutely 
regulate MRP2 activity. Figure 1c shows that intravenous administration of recombinant 
GLP-2 (125 µg/kg b.w.) significantly increases MRP2 activity (+210 %), evaluated after 
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on MRP2 activity. Using a previously established GLP-2 immunoneutralization strategy, 
we found that the effect of oleic acid was suppressed in the oleic acid + anti-GLP-2 group 
(Figure 1c), confirming GLP-2 participation. Pre-administration of anti-GLP-2 did not 
affect MRP2 activity in rats receiving oleic acid vehicle (data not shown), ruling out any 
effect of immunoneutralization procedure per se.
2.1.4. Extracellular adenosine synthesis takes place downstream GLP-2 and leads 
to increased MRP2 activity
After demonstrating GLP-2 role, we evaluated the participation of IGF-1 and adenosine 
as mediators of GLP-2 action. In the case of IGF-1, the experimental approach consisted 
of IGF-1 immunoneutralization. In the case of adenosine, it consisted of selective 
inhibition of the adenosine receptor A2BAR and inhibition of CD73, which is considered 
the most important enzyme in the generation of extracellular adenosine at the intestinal 
level.26,27 As shown in Figure 1d, the effect of oleic acid was not prevented by anti-IGF-1 
administration. In contrast, pre-treatment with MRS 1754 suppressed oleic acid effect on 
MRP2, confirming A2BAR participation. Moreover, APCP prevented the increase in 
MRP2 activity produced by both oleic acid and GLP-2 (Figure 1d), suggesting a role for 
extracellular adenosine in this effect and also establishing a sequence of events, with 
adenosine operating downstream GLP-2. Since pre-administration of anti-IGF-1, MRS 
1754 and APCP did not affect MRP2 activity in rats receiving oleic acid vehicle (data not 
shown), we ruled out any effect by these agents themselves. Adenosine per se, 
administered intravenously (10 mg/kg b.w.), significantly increased DNP-SG efflux (+222 
%; Figure 1d), confirming the ability of this nucleoside to modulate MRP2 activity when 
reaching the intestinal epithelium from the serosal side.
2.1.5. The stimulus generated by oleic acid is transmitted along the intestinal wall
After providing evidence supporting a role for specific mediators on the rapid action of 
oleic acid on MRP2 activity, the following question arose: how does the stimulus triggered 
by oleic acid in distal intestine reach the proximal jejunum? One possible transmission 
route is endocrine, with GLP-2 reaching systemic circulation after its release and finally 
acting at proximal jejunum. The other possibility is a transmission through the complex 
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oral and caudal directions.28 To distinguish between these possibilities, we sectioned the 
jejunum between the distal end of the intestinal sac and the site of administration of oleic 
acid, right before lipid administration. With this simple intervention, the neuronal 
connection between both regions of the jejunum is interrupted while the systemic 
connection remains unaffected. Figure 1e shows that jejunum sectioning limited the 
ability of oleic acid to enhance MRP2 activity. This finding is an unequivocal evidence of 
the participation of a transmission pathway that depends on the continuity of the intestine.
2.1.6. Oleic acid acutely increases apical MRP2 localization by a GLP-2-mediated 
mechanism
To assess whether these changes in MRP2 activity were correlated with changes in 
MRP2 subcellular localization, we performed a quantitative and qualitative confocal 
microscopy analysis. Figure 2 shows representative images of each group. In the upper 
panel images, channels corresponding to nuclei (blue) and MRP2 (red) are shown. The 
panels below show only the MRP2 channel in gray scale. The densitometric analysis is 
shown at the bottom. Acute, intraluminal treatment with oleic acid increased MRP2 
sorting from intracellular compartments to the apical membrane, as evidenced by a less 
dispersed signal along of the enterocytic longitudinal axis and more focused signal on the 
BBM region when compared to control group. Consistent with this qualitative 
interpretation, analysis of densitometric curves results in significantly higher MRP2 peak 
height (+185%) compared to control group. This higher density of transporter at the apical 
membrane of the enterocyte is in agreement with the reported increase in transport 
activity after oleic acid treatment. On the other hand, immunoneutralization of GLP-2 30 
min before treatment resulted in images, densitometric curve and MRP2 peak height 
similar to those from control group, demonstrating the participation of GLP-2 in the 
proinsertor effect of oleic acid (Figure 2).
2.2. In vitro studies: Elucidation of the intracellular mechanism involved in 
adenosine effects
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To elucidate the molecular mechanism downstream adenosine, we first confirmed the 
effect of this mediator on MRP2 activity through the evaluation of CDF efflux ratio across 
Caco-2 cell monolayers. Figure 3a shows that acute treatment with adenosine (50 µM) 
significantly increased CDF Papp in BA direction with respect to control cells, without 
changes in Papp in AB direction. This led to a significant increase in CDF efflux ratio, 
confirming that adenosine is able to increase MRP2 activity also in this model (Figure 
3b). In addition, we demonstrated that this effect was mediated by the A2BAR receptor, 
since increases in both CDF Papp in BA direction and CDF efflux ratio were prevented by 
the selective inhibitor MRS 1754 (Figure 3). MRS 1754 itself had no effect on CDF efflux 
ratio (MRS group; data not shown).
Finally, we evaluated the participation of PKA in adenosine-mediated increase of MRP2 
activity using KT5720. In the presence of this inhibitor, adenosine did not significantly 
modify CDF Papp in BA direction or CDF efflux ratio (Figure 3), confirming PKA 
mediation. However, because there were no differences between adenosine and 
adenosine + KT groups (Figure 3), PKA may not be the only mediator involved in the 
effects of adenosine. It is worth noting that KT5720 alone did not affect CDF efflux ratio, 
dismissing any possible unspecific effect of this agent in MRP2 activity (KT group; data 
not shown).
2.2.2. Adenosine acutely increases apical MRP2 localization through A2BAR 
activation
The next step was to assess whether the adenosine-dependent increase in MRP2 activity 
is associated to an increase in transporter apical insertion. Quantitative confocal 
microscopy studies showed that adenosine treatment (50 µM, 30 min) significantly 
increased MRP2 peak height, which was also found to be markedly displaced towards 
the apical surface of the monolayer (Figure 4). Images corresponding to the Z-stack 
adequately illustrate this finding, since adenosine-treated cells show apical MRP2 
concentration with concomitant decrease of the signal from intracellular regions when 
compared to control cells, which show a much more homogeneous MRP2 distribution 
along the Z axis (Figure 4). Panels on the right show that MRS 1754 (1 µM; A2BAR 
inhibitor) was able to prevent adenosine-induced changes in MRP2 distribution. These 
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translocation of MRP2 from intracellular reservoirs to the apical membrane, in an A2BAR-
mediated fashion.
2.2.3. Adenosine increases intracellular cAMP levels
Finally, considering that A2BAR is coupled to Gs, an adenylate cyclase activating protein, 
we assessed the intracellular cAMP levels after adenosine treatment (50 µM; 15 min). As 
result, we found a significant increase in Caco-2 cell lysates (269.5 ± 21.9 pmol/mL 
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3. Discussion
In this study we provide evidence supporting a novel physiological mechanism aimed at 
acutely regulating intestinal MRP2 activity in response to food intake, hence protecting 
the organism against the absorption of dietary toxicants. After our recent proof-of-concept 
article demonstrating the short-term regulation of intestinal MRP2,22 we focused on the 
development of an in vivo model with preserved irrigation and innervation that allows for 
detection of changes in MRP2 activity and localization in response to intraluminal 
administration of nutrients (section 4.2.2). This model was validated using the proinsertor 
agent dbcAMP (Figure 1a), intravenously administered at a dose known to be effective in 
modulating MRP2 in another highly perfused organ such as the liver.29 The differential 
effect of intraluminally administered agents on MRP2 activity (Figure 1b) is consistent 
with previous evidence demonstrating that GLP-2 secretion depends on the specific 
nutrient composition of the diet.23 Glucose exerted a dose-dependent action, with no 
effect at 10 mM and a statistically significant increase at 100 mM concentration (Figure 
1b). Considering that the intrajejunal glucose concentration after a meal ranges between 
0.4 and 24 mM in rats and between 0.5 and 40 mM in humans, depending whether it is 
distal or proximal jejunum,25 our finding at 100 mM may not have physiological relevance. 
Regarding glutamine, the work of Reimann et al.30 demonstrated the ability of a 10 mM 
concentration to stimulate GLP-1 secretion in an in vitro model. Since GLP-1 is co-
secreted with GLP-2 in equimolar amounts, this finding provided a rationale for inclusion 
of glutamine in the list of nutrients to be evaluated. However, the negative results (Figure 
1b) are rather aligned with in vivo studies ruling out a stimulatory effect of proteins and 
amino acids on GLP-2 secretion.20,31 Of the highest significance is the maximal response 
on MRP2 activity registered after oleic acid treatment (Figure 1b) at a physiologically 
relevant concentration.24 This led us to select this nutrient as the prototype to be used for 
the subsequent in vivo studies. This increase in transport activity was associated with 
MRP2 insertion on the apical membrane, evidenced by a higher MRP2 peak localized to 
the apical end of enterocytes and concomitant weaker signal from intracellular regions 
(Figure 2).
The participation of GLP-2 in oleic acid effect was demonstrated using an 
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intestinal growth secondary to streptozotocin-induced diabetes.32 This finding, supported 
by the effect of intravenously administered GLP-2 on MRP2 activity (Figure 1c), 
constitutes a new item in the increasing list of GLP-2 biological functions at the intestinal 
level.8,11,12,33-36 Regarding the molecular mechanism that follows GLP-2 secretion, we first 
evaluated the participation of IGF-1. This growth factor, although closely linked to GLP-2 
actions, was mainly associated with long-term effects such as proliferation and intestinal 
growth.14 Immunoneutralization of IGF-1 was unable to block the stimulating effect of 
oleic acid on MRP2 activity (Figure 1d). This would mean either that IGF-1 is not involved 
downstream GLP-2 or that the treatment was not effective enough to completely abolish 
IGF-1 activity. Additional experiments are required to properly distinguish between these 
two possibilities. In contrast, we identified adenosine as a valid candidate based on the 
results obtained using APCP (Figure 1d). Moreover, the evidence strongly suggests that 
extracellular adenosine synthesis by CD73 is a prerequisite for the effect of both oleic 
acid and GLP-2 on MRP2 activity. CD73, also known as ecto-5′-nucleotidase, mediates 
the generation of extracellular adenosine at the intestinal level.26,27 This process, of 
central role in both physiological and pathophysiological conditions, begins with ATP 
released by enteric neurons from submucosal and/or myenteric plexuses.37 ATP is then 
hydrolyzed by different ecto-nucleoside triphosphate diphosphohydrolases yielding AMP, 
which is further dephosphorylated to adenosine by CD73.38 cAMP was suggested as an 
alternative precursor to ATP in extracellular adenosine synthesis, in this case by tandem 
action of ecto-phosphodiesterase and CD73.27 With our experimental strategy it is not 
possible to ascertain whether ATP or cAMP constitutes the initial substrate in the 
cascade that culminates with CD73-dependent adenosine synthesis (Figure 5). Although 
we cannot rule out the participation of additional mediators such as IGF-1, it is 
noteworthy that the administration of either APCP or MRS 1754 (Figure 1d) was capable 
of abolishing oleic acid stimulation of MRP2 activity. This is consistent with a major role 
for GLP-2/extracellular adenosine/A2BAR pathway in oleic acid effects. Finally, 
experiments involving sectioning of the intestine demonstrate that the effects reported for 
oleic acid totally depended on the preservation of the structure and continuity of the 
intestinal wall, indirectly ruling out the intervention of systemic circulation (Figure 1e). 
Considering both GLP-2R expression in enteric neurons13 and the deep innervation of 
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multiple neurons from submucosal and/or myenteric plexuses seems the most likely. 
Figure 5 illustrates only one of the possibilities, since other more complex alternatives to 
the one represented, such as the participation of more than one neuronal type, cannot be 
ruled out. In this regard, signal transmission in caudal-oral direction may involve intrinsic 
primary afferent neurons, ascending interneurons and motor neurons.28 Additional 
experiments including synaptic transmission blockades may contribute to clarify this 
route.
Due to the technical difficulties inherent in establishing a primary enterocyte culture, 
Caco-2 intestinal cells were chosen to evaluate the intracellular mechanism. Despite their 
colonic origin, Caco-2 cells undergo spontaneous differentiation after 21 days of culture 
to form a confluent monolayer of enterocyte-like polarized cells, which structurally and 
functionally resembles the small intestinal epithelium.40-42 Regarding expression of the 
most relevant intestinal transporters (including MRP2), different studies demonstrated a 
similar pattern between differentiated Caco-2 cells and human small intestine.43-45 Thus, 
Caco-2 cell monolayers grown on permeable supports constitute an optimal in vitro 
model system for drug transport studies.40 In addition, using confocal microscopy and 
membrane fractionation followed by immunoblotting studies, rapid changes in MRP2 
localization were already confirmed in these cells.22 In the current work we demonstrated 
that acute treatment with adenosine led to a significant increase in MRP2 activity (Figure 
3b) which was associated with apical insertion of the transporter (Figure 4). These 
findings complement those resulting from in vivo studies (Figure 1d), and demonstrate for 
the first time adenosine modulatory action on both human and murine intestinal MRP2. 
Interestingly, interstitial adenosine levels in the jejunum are increased up to two orders of 
magnitude during post-intake periods, a situation so far associated with postprandial 
jejunal hyperemia.46,47 Based on our findings, we suggest that postprandial adenosine 
boost not only leads to increased intestinal blood flow but also contributes to strengthen 
the intestinal barrier function provided by MRP2.
The effect of adenosine on MRP2 activity and localization in Caco-2 cells was mediated 
by A2BAR (Figure 3 and Figure 4). Within adenosine receptors, A2BAR is the most 
relevant in the intestine and is expressed, among other sites, at epithelial level.48,49 Since 
it is coupled to G stimulatory protein, an increase in cAMP synthesis by adenylate 
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monolayers demonstrated that activation of A2BAR/cAMP/PKA axis by adenosine 
stimulates polarized apical secretion of the proinflammatory cytokine IL-6.50 Considering 
that several compounds with proinflammatory activity such as prostaglandins or 
leukotrienes are MRP2 substrates,1,2 it is possible that this regulation takes place also 
under pathophysiological conditions, e.g. to deal with intraluminal pathogens. In our 
experimental conditions, intracellular levels of cAMP were also significantly increased in 
response to adenosine stimulation after a 15-min treatment (section 2.2.3). This result 
provides evidence in support of adenosine/A2BAR/adenylate cyclase axis functionality in 
our experimental model. We also found that PKA participation is necessary to explain, at 
least in part, modulation of MRP2 activity by adenosine (Figure 3). These findings agree 
with previous evidence in hepatic and intestinal models demonstrating the ability of 
cAMP/PKA axis to acutely increase MRP2 activity.22,51 However, it is important to note 
that cAMP increase not only leads to PKA activation, but can also increase the activity of 
other kinases such as exchange protein directly activated by cAMP, phosphoinositide 3-
kinase or p38 mitogen-activated protein kinases, all of them also able to acutely modulate 
MRP2 localization in hepatic models.51 Additional studies are necessary to further 
determine the eventual participation of kinases other than PKA.
Our in vivo model allows for evaluation of the effect of GLP-2 produced only by direct 
stimulation of L cells by nutrients, and does not consider the effect of GLP-2 produced by 
indirect mechanisms in response to the presence of nutrients in the duodenum. This 
mechanism involving participation of vagal fibers and nicotinic synapses18 results in 
earlier L cell stimulation and complements the effect here described. Regarding the time 
of permanence of nutrients in the small intestine, a transit time between one and four 
hours has been estimated, regardless of whether they are originated in solid or liquid 
foods.52 Sustained secretion of GLP-2 along the whole digestive process would provide 
an enhanced barrier function in order to deal with the exposition to potentially harmful 
components of the diet.
Because of its preferential localization at the proximal region of the small intestine, MRP2 
exerts a significant function in reducing the body load of potentially harmful compounds 
entering the digestive tract. Although with different distribution along the intestine, other 
ABC transporters expressed at the BBM of the enterocyte provide a similar barrier 
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nutrients and cannot ascertain whether other members of the ABC family would be 
affected in a similar fashion. To our knowledge, there is no information in the literature 
describing such effect. If demonstrated, it would represent a regulation complementary to 
MRP2 since a broader substrate specificity and a more extensive intestinal region will be 
covered. In addition to the barrier function, this physiological mechanism could also 
improve nutrient absorption during the course of a meal if demonstrated for intestinal 
uptake proteins such as solute carrier transporters. In this regard, Cheeseman made a 
substantial contribution by reporting increased sodium-dependent glucose uptake in rat 
jejunum BBM vesicles after 30 min of GLP-2 intravenous treatment. This was associated 
with increased SGLT-1 localization in BBM. Based on the results obtained using 
wortmannin, the author proposes phosphoinositide 3-kinase as the mediator of this acute 
GLP-2 effect.54
The main conclusion of this work is summarized in Figure 5. After intake, the presence of 
nutrients such as oleic acid in the intestinal lumen triggers GLP-2 release by 
enteroendocrine L cells, presumably by both indirect and direct mechanisms. GLP-2, 
secreted through the basolateral membrane into the interstitial space, would activate its 
receptor in enteric neurons. As a consequence, the generated stimulus would be 
transmitted along the intestinal wall, eventually involving participation of more neurons or 
other cellular types. AMP precursors such as ATP or cAMP are likely secreted by these 
neurons, although the intervention of some other cell type in the proximity of the 
enterocyte cannot be ruled out. AMP is then hydrolyzed by CD73 yielding adenosine, 
which directly activates A2BAR at the basolateral membrane of the enterocyte. This 
activation results in increased intracellular cAMP concentrations, ultimately stimulating 
MRP2 insertion from intracellular reservoirs to BBM in a process mediated, at least in 
part, by PKA. This increase in MRP2 density at the apical membrane is associated with 
increased transport activity and thus increased membrane barrier function. An additional 
contribution of our study is that, during fasting periods, GLP-2- MRP2 interaction is 
expected to decrease due to absence of stimuli on intestinal L cells. This event, also 
physiologic, would result in decreased MRP2 apical localization and activity, saving 
metabolic energy and avoiding the unnecessary luminal secretion of valuable substrates 
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4. Materials and Methods
4.1. Chemicals
Adenosine, adenosine 5′-(α,β-methylene) diphosphate (APCP), 5(6)-carboxy-2′,7′-
dichlorofluorescein diacetate (CDFDA), 1-chloro-2,4-dinitrobenzene (CDNB), dbcAMP, 
glucose, glutamine and MRS 1754 were purchased from Sigma-Aldrich (Missouri, USA); 
anti-GLP-2 (C-20) and KT5720 were purchased from Santa Cruz Biotechnology (Dallas, 
USA); anti-IGF-1 (M23) was purchased from ThermoScientific (Illinois, USA); rat 
recombinant GLP-2 was purchased from Abcam (Cambridge, UK) and double-distilled 
oleic acid was purchased from Ballester Productos Químicos S.A. (Villa Ballester, 
Argentina). DNP-SG was synthesized using 1-fluoro-2,4-dinitrobenzene and glutathione 
as described by Sokolovsky et al.55 All other chemicals were of analytical grade purity or 
higher.
4.2. In vivo studies
4.2.1. Animals
Adult male Wistar rats (310 - 330 g) were supplied by Centro de Medicina Comparada 
(UNL - CONICET, Esperanza, Argentina). They were maintained with a standard diet and 
tap water ad libitum in a room with controlled temperature and humidity and a 12-12 h 
light-dark cycle. The rats were fasted for 12 hours before the experiments. At the time of 
the experiments, they were anesthetized using ketamine + xylazine (ketamine: 100 mg/kg 
b.w; xylazine: 15 mg/kg b.w.; i.p) and, after that, their body temperature was monitored 
and maintained between 37°C and 37.5°C using heating lamps. All procedures involving 
animals were in accordance with the ‘European Convention for the Protection of 
Vertebrate Animals used for Experimental and Other Scientific Purposes’ and were 
approved by the Bioethical Committee for the Management of Laboratory Animals from 
the Faculty of Biochemical and Pharmaceutical Sciences of the National University of 
Rosario (Res. 410/2014).
4.2.2. In vivo model
The in vivo model used in this work allows for direct stimulation of GLP-2-producing L 
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colon) with simultaneous evaluation of MRP2 activity and localization in the intestinal 
region exhibiting the highest MRP2 expression (proximal jejunum) (see Figure 6a). In 
addition, this model preserves intestinal irrigation and innervation.
4.2.3. Intraluminal and intravenous treatments
To evaluate the effect of GLP-2 secretion stimulators on MRP2 activity and localization, 
2.5 mL of oleic acid (10 % V/V in saline + 3 % Tween 20; pH = 6.5),24 glucose (10 and 
100 mM in saline, pH = 6.5),56 glutamine (10 and 100 mM in saline, pH = 6.5),30 saline + 
3 % Tween 20 or saline alone were gently injected into distal jejunum (approximately 19 
cm after the ligament of Treitz) using a 25G needle. During this procedure, the region of 
the intestine proximal to the site of administration was occluded with a thread to avoid 
retrograde flow of the agents. After 20 min of treatment, MRP2 activity studies were 
performed.
For systemic treatments, the femoral vein was catheterized with polyethylene tubing (PE-
40) and dbcAMP (20 µmol/kg b.w. in 0.4 mL of saline), GLP-2 (125 µg/kg b.w. in 0.4 mL 
of saline), adenosine (10 mg/kg b.w. in 0.4 mL of saline) or saline alone were 
administered.29,57,58 After 20 min, MRP2 activity studies were performed. In the case of 
adenosine, the total volume was administered in four doses of 0.1 mL each, with 5-min 
intervals. All these procedures are illustrated in Figure 6b.
To gain insight into the mechanism of stimulation by oleic acid, immunoneutralization of 
GLP-2 and IGF-1 was performed by intraperitoneal injections of anti-GLP-2 (20 µg in 1 
mL of saline) or anti-IGF-1 (50 µg in 1 mL of saline) respectively, 30 min before 
administration of this nutrient.32 Identical experiments of immunoneutralization with anti-
IGF-1 and anti-GLP-2 were performed with animals receiving only the vehicle of oleic 
acid. To evaluate the participation of extracellular adenosine in the signaling mechanism, 
the selective CD73 inhibitor APCP (2 mg/kg b.w. in 1 mL of saline) and the selective A2B 
adenosine receptor (A2BAR) inhibitor MRS 1754 (0.5 mg/kg b.w. in 1 mL of saline) were 
intraperitoneally administered 30 min before administration of oleic acid or GLP-2.59,60 
Identical experiments of inhibition with APCP and MRS 1754 were performed replacing 
oleic acid and GLP-2 by the respective vehicles. Finally, to evaluate the participation of 
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administration (i.e. approximately 17 cm after the ligament of Treitz), just before 
intraluminal treatment with oleic acid. All these procedures are illustrated in Figure 6c.
4.2.4. MRP2 activity studies
During the 20-min treatments, the 15-cm proximal jejunum segment for evaluation of 
DNP-SG (i.e. model substrate of MRP2) efflux was delimited. The proximal and distal 
ends of this segment (located 1 cm and 16 cm after the ligament of Treitz, respectively) 
were identified with pre-assembled, untied knots. Once the treatment was completed, the 
distal end knot was tied, the segment was filled with 2.6 mL of a 100 µM CDNB solution 
in Krebs-Henseleit buffer and finally the proximal end knot was tied, completely closing 
the intestinal sac. The incubation time under these conditions was 30 min. Afterwards, 
the animal was sacrificed by exsanguination and the intestinal sac was removed. After 
sac length measurement, the content was collected in a graduated tube and its volume 
was recorded. After deproteinization, the solution was subjected to quantification of DNP-
SG and its dinitrophenyl-cysteinyl glycine derivative (DNP-CG) by HPLC-UV as 
previously described.61 DNP-SG + DNP-CG mass was calculated using their 
concentration and the volume measurements of the intestinal sac content. DNP-CG is 
produced by the action of γ-glutamyltransferase on DNP-SG at the BBM after this 
compound reaches the mucosal compartment.62 Therefore, the excretion rate of DNP-SG 
+ DNP-CG adequately estimates MRP2 activity. These procedures are summarized in 
Figure 6d.
4.2.5. MRP2 localization studies
MRP2 localization studies were performed by immunostaining followed by quantitative 
confocal microscopy. Rats were treated with intraluminal saline (control group), 
intraluminal oleic acid (oleic acid group) or intraluminal oleic acid with anti-GLP-2 
pretreatment (oleic acid + anti-GLP-2 group) as previously described. After sacrifice by 
exsanguination, a segment from proximal jejunum was carefully washed and frozen in 
liquid 1,1,1,2-tetrafluoroethane (Electroquímica DELTA SRL, Buenos Aires, Argentina). 
The segment was cut into slices of 5 µm thick with a microtome cryostat (HM 500, 
Microm International GmbH, Walldorf, Germany) and mounted on slides. Preparations 
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using anti-MRP2: M2III-6 (1:100) from Enzo Life Sciences (Farmingdale, USA) followed 
by incubation with anti-mouse IgG conjugated with Alexa Fluor 555 (1:300) from 
ThermoScientific (Illinois, USA). Nuclei were detected using Hoechst 33258 from Santa 
Cruz Biotechnology (Dallas, USA). At least 8 images per group were captured using a 
Nikon C1+ confocal system built onto a Nikon TE2000 inverted microscope with a 60X 
Plan Apo NA 1.4 objective. Images were then analyzed using ImageJ software (NIH, 
Bethesda, USA). To establish the relative MRP2 distribution with respect to the nuclei, 
MRP2 and nuclei channels were separated and the distribution of the fluorescence 
intensity along the longitudinal axis of the enterocyte was evaluated (see Figure 7). The 
total area under the curves were assigned the same arbitrary value and the maximum 
value of MRP2 fluorescence intensity (peak height) was compared between groups as a 
quantitative measurement of MRP2 distribution. For data presentation, maximum 
fluorescence intensity values of the nuclei were aligned to qualitatively reveal eventual 
changes in MRP2 cellular distribution in response to treatments.
4.3. In vitro studies
4.3.1. Caco-2 cell culture
Caco-2 cells were obtained from the American Tissue Culture Collection (Manassas, 
USA) and grown in DMEM (Gibco; Carlsbad, USA) supplemented with 10% V/V fetal 
bovine serum (Natocor; Córdoba, Argentina), 1 % V/V non-essential amino acids, 2 mM 
L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco; Carlsbad, USA). 
Cells were grown at 37°C in a humid atmosphere containing 5 % CO2.
4.3.2. MRP2 activity studies
For MRP2 activity studies, 3 × 105 cells/well were seeded in 12-well Transwell® 
permeable supports (cat. No. 3401; Corning Inc., Corning, USA) and cultured for 21 days 
as described by Hubatsch et al.40 Culture medium in both apical and basolateral 
compartments was replaced every second day. To evaluate monolayer integrity, 
transepithelial electrical resistance (TEER) was monitored every second day using an 
epithelial voltohmmeter (EVOM; World Precision Instruments, Sarasota, USA). All cell 
monolayers used in the experiments had TEER values at 37°C above 300 Ω cm2, 









This article is protected by copyright. All rights reserved
MRP2 activity was evaluated by assessing the ratio between the apical-to-basolateral 
(AB) and the basolateral-to-apical (BA) directional transport of the prototypical MRP2 
substrate 5(6)-carboxy-2′,7′-dichlorofluorescein (CDF) as previously described.61 The 
CDF non-fluorescent promoiety, CDFDA, is taken up passively by Caco-2 cells and 
immediately hydrolyzed by intracellular esterases to the fluorescent CDF.64 Briefly, prior 
to the activity measurement, cell monolayers were washed with Hank's balanced salt 
solution (HBSS) for 15 min at 37°C. Afterwards, cells were treated with culture medium 
alone (control group) or culture medium containing 50 µM adenosine (adenosine group), 
50 µM adenosine + 10 µM MRS 1754 (adenosine + MRS group), 50 µM adenosine + 1 
µM KT5720 (adenosine + KT group), 10 µM MRS 1754 (MRS group) or 1 µM KT5720 
(KT group).22,65,66 After 20 min of treatment, cells were washed with HBSS alone (control 
group) or HBSS containing 50 µM adenosine (adenosine group), 50 µM adenosine + 10 
µM MRS 1754 (adenosine + MRS group), 50 µM adenosine + 1 µM KT5720 (adenosine 
+ KT group), 10 µM MRS 1754 (MRS group) or 1 µM KT5720 (KT group) for 15 min at 
37°C. Then, filter inserts were transferred to new plates and CDFDA (10 μM, in HBSS) 
was added to the donor compartment (apical for AB direction experiments, basolateral for 
BA direction experiments). The receiving compartment (basolateral for AB direction 
experiments, apical for BA direction experiments) was filled with pre-warmed HBSS. 
Plates were then placed in a 37°C incubator and samples from the receiving 
compartment were withdrawn with volume replacement every 30 min up to 120 min. CDF 
was quantified using a DTX 880 fluorometer (Beckman Coulter; Brea, USA) set at 485 
nm/520 nm for excitation and emission wavelengths, respectively. Apparent permeability 
coefficients (Papp, cm.s−1) of CDF across cell monolayers in both AB and BA directions 
were calculated using the following equation:






where dQ/dt is the appearance rate of CDF on the receiving compartment, C0 is the initial 
CDFDA concentration in the donor compartment (10 μM) and A is the Transwell® support 
surface area (1.12 cm2). CDF efflux ratio was obtained by dividing Papp in the BA direction 
by Papp in the AB direction.
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To detect MRP2 localization in Caco-2 cells, a sterile coverslip was placed in each well of 
6-well plates; 2.5 × 105 cells were seeded on each coverslip and cultured for 21 days as 
described. Then, differentiated cells were treated with culture medium alone (control 
group) or culture medium containing 50 µM adenosine (adenosine group) or 50 µM 
adenosine + 10 µM MRS 1754 (adenosine + MRS group). After 30 min of treatment, 
immunostaining of MRP2 and nuclei was performed as described earlier in this section. 
Optical sections (23-31 z-series) were collected with a step size of 0.4 µm. Images are 
shown as top and 3D orthogonal views. The densitometric study was similar to that 
performed for intestinal segments, except that the determination of fluorescence intensity 
was performed along the z axis, using a 10 µm line.
4.3.4. Quantification of intracellular cAMP
To quantify intracellular levels of cAMP, 2.5 × 105 cells/well were seeded in 6-well plates 
and cultured for 21 days. Then, they were incubated with culture medium alone (control 
group) or culture medium containing 50 µM adenosine (adenosine group) for 15 min. 
Immediately afterwards, cells were washed with PBS and lysed in HCl (0.1 M, 20 min) at 
room temperature in order to stop phosphodiesterase activity and stabilize the released 
cAMP.67,68 Finally, cAMP was quantified using the cAMP Select ELISA kit (Cayman 
Chemical, Ann Arbor, USA) according to the manufacturer's instructions.
4.4. Statistical analysis
All results were expressed as mean ± standard deviation. Statistical comparisons were 
performed through the Student's t-test (two experimental groups) or through ANOVA 
followed by Tukey (more than two experimental groups). Statistical significance was set 
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Figure legends
Fig. 1 In vivo studies: Effect of nutrients on MRP2 activity and elucidation of the 
extracellular mechanism involved.
a. The increase in MRP2 activity after intravenous administration of dbcAMP (20 µmol/kg 
b.w.; 20 min) validated the current model. b. Effect of intraluminal administration of 
glucose (Glc), oleic acid (OA) and glutamine (Gln) on MRP2 activity. c. Modulation of 
MRP2 activity after intravenous GLP-2 administration and participation of this peptide in 
oleic acid effect. d. Evaluation of the mechanism downstream GLP-2, including the 
mediators IGF-1 and adenosine. e. Jejunum sectioning before oleic acid treatment 
confirmed that the stimulus triggered by the lipid is transmitted along the intestinal wall. 
Data are presented as % of the corresponding control group and expressed as mean ± 
standard deviation (n = 4). *: p < 0.05
Fig. 2 In vivo studies: Oleic acid acutely increases apical MRP2 localization by a 
GLP-2-mediated mechanism.
MRP2 was labeled with Alexa Fluor 555 (red fluorescence) and nuclei were stained with 
the blue dye Hoechst 33258 (images from the top row). For the sake of clarity, grayscale 
images are included showing only the MRP2 channel. Fluorescence intensity distribution 
along a 30 µm line parallel to the longitudinal axis of the enterocyte (distance represented 
in x-axis) was evaluated for red and blue channels (n = 20 per group). To detect changes 
in the distribution of MRP2 curve, all data sets were scaled to the same arbitrary area 
under the curve value and the resulting curves were aligned using the nuclei channel as 
a reference. Additionally, MRP2 peak height was calculated, expressed as mean ± 
standard deviation and compared between groups. *: p < 0.05 versus the two remaining 
groups. White scale bar represents 10 µm
Fig. 3 Studies in Caco-2 cells: Adenosine acutely increases MRP2 activity through 
A2BAR and PKA activation.
a. Permeability coefficients (Papp) of the MRP2 substrate CDF after 120 min, in both 
apical to basolateral (AB) and basolateral to apical (BA) directions. b. The CDF efflux 
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activity. MRS: 10 µM MRS 1754. KT: 1 µM KT5720. Data are expressed as mean ± 
standard deviation (n = 4). *: p < 0.05
Fig. 4 Studies in Caco-2 cells: Adenosine acutely increases apical MRP2 
localization through A2BAR activation.
Main images represent the top view of the cell monolayer. Images created by stacking 
along the Z axis are shown on the right and at the bottom. A small region of the Z-axis 
images from each group is shown with higher magnification as an inset. MRP2 was 
labeled with red fluorescence whereas the nuclei, in blue, were stained with Hoechst 
33258. Fluorescence intensity distribution along a 10 µm line parallel to the longitudinal 
axis of the cells (distance represented in x-axis) was evaluated for red and blue channels 
(n = 20 per group). To detect changes in the distribution of MRP2 among groups, all data 
sets were scaled to the same arbitrary area under the curve value and the resulting 
curves were aligned using the nuclei channel as a reference. Additionally, MRP2 peak 
height was calculated, expressed as mean ± standard deviation and compared between 
groups. * p < 0.05 versus the two remaining groups. White scale bar represents 10 µm
Fig. 5 Sequence of events in the regulation of MRP2 by oleic acid.
Taken together, the data allow us to propose the following sequence of events. After 
ingestion, intraluminal oleic acid stimulates intestinal L cells to release GLP-2 towards the 
basolateral pole (1). GLP-2 in turn binds to its receptor in enteric neurons (2) which, 
either by themselves or through activation of other cell types, release one or more of the 
possible adenosine precursors (3). CD73 catalyzes the hydrolysis of extracellular AMP to 
adenosine (4), a nucleoside able to increase MRP2 apical localization and activity in the 
enterocyte via the A2BAR/cAMP/PKA axis (5)
Fig. 6 In vivo model for assessment MRP2 activity and localization.
a. Studies were performed in two well identified and separated regions based on the 
highest MRP2 expression (proximal jejunum) and the highest presence of GLP-2 
producing L cells (distal jejunum and ileum). b. For direct stimulation of L cells, nutrients 
were intraluminally incorporated into distal jejunum (left panel). In contrast, and due to 
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systemically administered into the femoral vein (right panel). After 20 min of treatment, 
MRP2 activity was determined. c. Pretreatments to assess mechanistical aspects 
underlying oleic acid effect consisted of both the immunoneutralization of GLP-2 or IGF-1 
and the inhibition of CD73 or A2BAR by intraperitoneal injection of antibodies or selective 
inhibitors, respectively (left panel). To assess whether the signal triggered by oleic acid is 
transmitted along the intestinal wall, the jejunum was sectioned to physically separate the 
two regions referred above (right panel). All these procedures were followed by oleic acid 
intraluminal treatment. d. After treatments, DNP-SG efflux was determined to estimate 
MRP2 activity. For that purpose, a 15 cm intestinal sac was created right after the 
ligament of Treitz (proximal jejunum) and filled with a solution of the parent compound 
CDNB. After 30 min, the amount of DNP-SG secreted to the luminal compartment was 
quantified by HPLC-UV
Fig. 7 MRP2 localization studies: densitometric data collection.
All procedures were performed using ImageJ software on images obtained by confocal 
microscopy. a. Distribution of fluorescence intensity was evaluated along a 30 µm line 
parallel to the longitudinal axis of the enterocyte. b. Next, the channels corresponding to 
the nuclei (graph on the left) and MRP2 (graph on the right) were separated and plotted. 
This procedure was repeated until obtaining 20 pairs of graphs for each experimental 
group
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